These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 20226659

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG, Chen KX, Shih NY, Piwinski JJ.
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [Abstract] [Full Text] [Related]

  • 3. Potent aza-peptide derived inhibitors of HCV NS3 protease.
    Venkatraman S, Wu W, Shih NY, George Njoroge F.
    Bioorg Med Chem Lett; 2009 Aug 15; 19(16):4760-3. PubMed ID: 19596195
    [Abstract] [Full Text] [Related]

  • 4. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
    Avolio S, Robertson K, Hernando JI, DiMuzio J, Summa V.
    Bioorg Med Chem Lett; 2009 Apr 15; 19(8):2295-8. PubMed ID: 19285390
    [Abstract] [Full Text] [Related]

  • 5. Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
    Bogen SL, Pan W, Ruan S, Nair LG, Arasappan A, Bennett F, Chen KX, Jao E, Venkatraman S, Vibulbhan B, Liu R, Cheng KC, Guo Z, Tong X, Saksena AK, Girijavallabhan V, Njoroge FG.
    J Med Chem; 2009 Jun 25; 52(12):3679-88. PubMed ID: 19456105
    [Abstract] [Full Text] [Related]

  • 6. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K, Kwo PY.
    Clin Liver Dis; 2009 Aug 25; 13(3):429-39. PubMed ID: 19628159
    [Abstract] [Full Text] [Related]

  • 7. Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.
    Venkatraman S, Velazquez F, Wu W, Blackman M, Chen KX, Bogen S, Nair L, Tong X, Chase R, Hart A, Agrawal S, Pichardo J, Prongay A, Cheng KC, Girijavallabhan V, Piwinski J, Shih NY, Njoroge FG.
    J Med Chem; 2009 Jan 22; 52(2):336-46. PubMed ID: 19102654
    [Abstract] [Full Text] [Related]

  • 8. A review of HCV protease inhibitors.
    Chen KX, Njoroge FG.
    Curr Opin Investig Drugs; 2009 Aug 22; 10(8):821-37. PubMed ID: 19649927
    [Abstract] [Full Text] [Related]

  • 9. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX, Njoroge FG, Arasappan A, Venkatraman S, Vibulbhan B, Yang W, Parekh TN, Pichardo J, Prongay A, Cheng KC, Butkiewicz N, Yao N, Madison V, Girijavallabhan V.
    J Med Chem; 2006 Feb 09; 49(3):995-1005. PubMed ID: 16451065
    [Abstract] [Full Text] [Related]

  • 10. Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
    Arasappan A, Padilla AI, Jao E, Bennett F, Bogen SL, Chen KX, Pike RE, Sannigrahi M, Soares J, Venkatraman S, Vibulbhan B, Saksena AK, Girijavallabhan V, Tong X, Cheng KC, Njoroge FG.
    J Med Chem; 2009 May 14; 52(9):2806-17. PubMed ID: 19371095
    [Abstract] [Full Text] [Related]

  • 11. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
    Thomson JA, Perni RB.
    Curr Opin Drug Discov Devel; 2006 Sep 14; 9(5):606-17. PubMed ID: 17002221
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Potent inhibitors of HCV-NS3 protease derived from boronic acids.
    Venkatraman S, Wu W, Prongay A, Girijavallabhan V, George Njoroge F.
    Bioorg Med Chem Lett; 2009 Jan 01; 19(1):180-3. PubMed ID: 19022670
    [Abstract] [Full Text] [Related]

  • 15. Investigation of glycine alpha-ketoamide HCV NS3 protease inhibitors: effect of carboxylic acid isosteres.
    Han W, Jiang X, Hu Z, Wasserman ZR, Decicco CP.
    Bioorg Med Chem Lett; 2005 Aug 01; 15(15):3487-90. PubMed ID: 15982872
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species.
    Bogen SL, Arasappan A, Velazquez F, Blackman M, Huelgas R, Pan W, Siegel E, Nair LG, Venkatraman S, Guo Z, Doll R, Shih NY, Njoroge FG.
    Bioorg Med Chem; 2010 Mar 01; 18(5):1854-65. PubMed ID: 20149666
    [Abstract] [Full Text] [Related]

  • 18. Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
    Lampa A, Ehrenberg AE, Gustafsson SS, Vema A, Kerblom E, Lindeberg G, Karlén A, Danielson UH, Sandström A.
    Bioorg Med Chem; 2010 Jul 15; 18(14):5413-24. PubMed ID: 20541424
    [Abstract] [Full Text] [Related]

  • 19. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections.
    Venkatraman S.
    Trends Pharmacol Sci; 2012 May 15; 33(5):289-94. PubMed ID: 22521415
    [Abstract] [Full Text] [Related]

  • 20. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
    Johansson PO, Bäck M, Kvarnström I, Jansson K, Vrang L, Hamelink E, Hallberg A, Rosenquist A, Samuelsson B.
    Bioorg Med Chem; 2006 Aug 01; 14(15):5136-51. PubMed ID: 16675222
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.